Abstract
The three main sections in this article illustrate a number of facets of European health care. The first section looks at the influence of NICE on treatment of metastatic castration-resistant prostate cancer. The second section explores the impact of molecular imaging on diagnosis and treatment, in particular the development and clinical implementation of 68Ga PET imaging in prostate cancer. The final section of the session looks at the STAMPEDE trial and how running a trial on this scale has impacted care of prostate cancer in the United Kingdom and also at the uptake of docetaxel chemotherapy in hormone-sensitive advanced disease.
| Original language | English |
|---|---|
| Pages (from-to) | 344-357 |
| Number of pages | 14 |
| Journal | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting |
| Volume | 37 |
| DOIs | |
| State | Published - 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver